Wall Street brokerages expect that Aclaris Therapeutics (NASDAQ:ACRS) will announce earnings of ($0.99) per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Aclaris Therapeutics’ earnings. The highest EPS estimate is ($0.94) and the lowest is ($1.06). Aclaris Therapeutics posted earnings of ($0.48) per share during the same quarter last year, which indicates a negative year-over-year growth rate of 106.3%. The business is expected to announce its next earnings report on Tuesday, May 8th.
On average, analysts expect that Aclaris Therapeutics will report full year earnings of ($4.27) per share for the current financial year, with EPS estimates ranging from ($4.64) to ($3.85). For the next year, analysts forecast that the business will report earnings of ($3.32) per share, with EPS estimates ranging from ($3.89) to ($2.87). Zacks Investment Research’s earnings per share averages are an average based on a survey of sell-side research firms that cover Aclaris Therapeutics.
Aclaris Therapeutics (NASDAQ:ACRS) last released its quarterly earnings results on Monday, March 12th. The biotechnology company reported ($0.80) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.90) by $0.10. The business had revenue of $1.00 million for the quarter, compared to analysts’ expectations of $0.80 million.
Aclaris Therapeutics stock traded down $0.20 during mid-day trading on Friday, reaching $16.46. 194,484 shares of the company’s stock traded hands, compared to its average volume of 322,198. The company has a market cap of $512.35, a price-to-earnings ratio of -6.58 and a beta of 1.63. Aclaris Therapeutics has a 12-month low of $16.01 and a 12-month high of $33.10.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Teachers Advisors LLC grew its holdings in shares of Aclaris Therapeutics by 8.4% in the fourth quarter. Teachers Advisors LLC now owns 42,099 shares of the biotechnology company’s stock worth $1,038,000 after purchasing an additional 3,273 shares during the last quarter. Rosenblum Silverman Sutton S F Inc. CA grew its holdings in shares of Aclaris Therapeutics by 11.1% in the fourth quarter. Rosenblum Silverman Sutton S F Inc. CA now owns 46,200 shares of the biotechnology company’s stock worth $1,139,000 after purchasing an additional 4,600 shares during the last quarter. Alps Advisors Inc. grew its holdings in shares of Aclaris Therapeutics by 15.7% in the fourth quarter. Alps Advisors Inc. now owns 34,168 shares of the biotechnology company’s stock worth $843,000 after purchasing an additional 4,626 shares during the last quarter. Cubist Systematic Strategies LLC bought a new position in shares of Aclaris Therapeutics in the third quarter worth about $142,000. Finally, Redmile Group LLC grew its holdings in shares of Aclaris Therapeutics by 6.0% in the fourth quarter. Redmile Group LLC now owns 107,020 shares of the biotechnology company’s stock worth $2,639,000 after purchasing an additional 6,060 shares during the last quarter. Hedge funds and other institutional investors own 92.19% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Ticker Report and is the property of of Ticker Report. If you are reading this news story on another domain, it was stolen and republished in violation of US & international trademark and copyright laws. The correct version of this news story can be accessed at https://www.tickerreport.com/banking-finance/3336131/zacks-brokerages-anticipate-aclaris-therapeutics-acrs-to-announce-0-99-eps.html.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies to address the unmet needs in medical and aesthetic dermatology and immunology in the United States. The company operates in two segments, Dermatology Therapeutics and Contract Research.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.